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IMPORTANCE Shared decisionmaking helps patients and clinicians elect therapies aligned
with patients’ values and preferences. This is particularly important for invasive therapies
with considerable trade-offs.
OBJECTIVE To assess the effectiveness of a shared decision support intervention for patients
considering destination therapy left ventricular assist device (DT LVAD) placement.
DESIGN, SETTING, AND PARTICIPANTS From 2015 to 2017, a randomized, stepped-wedge trial
was conducted in 6 US LVAD implanting centers including 248 patients being considered for
DT LVAD. After randomly varying time in usual care, sites were transitioned to an intervention
consisting of clinician education and use of DT LVAD pamphlet and video patient decision
aids. Follow up occurred at 1 and 6months.
MAIN OUTCOMES ANDMEASURES Decision quality asmeasured by knowledge and
values-choice concordance.
RESULTS In total, 135 patients were enrolled during control and 113 during intervention
periods. At enrollment, 59 (23.8%) participants were in intensive care, 60 (24.1%) were older
than 70 years, 39 (15.7%) were women, 45 (18.1%) were racial/ethnic minorities, and 62
(25.0%) were college graduates. Patient knowledge (mean test performance) during the
decision-making period improved from 59.5% to 64.9% in the control group vs 59.1% to
70.0% in the intervention group (adjusted difference of difference, 5.5%; P = .03). Stated
values at 1 month (scale 1 = “do everything I can to live longer…” to 10 = “live with whatever
time I have left…”) were a mean of 2.37 in control and 3.33 in intervention (P = .03).
Patient-reported treatment choice at 1 month favored LVADmore in the control group (than
in the intervention group (47 [59.5%] vs 95 [91.3%], P < .001). Correlation between stated
values and patient-reported treatment choice at 1 month was stronger in the intervention
group than in the control group (difference in Kendall’s τ, 0.28; 95% CI, 0.05-0.45); however,
there was no improved correlation between stated values and actual treatment received by 6
months for the intervention compared with the control group (difference in Kendall’s τ, 0.01;
95% CI, −0.24 to 0.25). The adjusted rate of LVAD implantation by 6months was higher for
those in the control group (79.9%) than those in the intervention group (53.9%, P = .008),
with significant variation by site. There were no differences in decision conflict, decision
regret, or preferred control.
CONCLUSIONS AND RELEVANCE A shared decision-making intervention for DT LVADmodestly
improved patient decision quality as measured by patient knowledge and concordance
between stated values and patient-reported treatment choice, but did not improve
concordance between stated values and actual treatment received. The rate of implantation
of LVADs was substantially lower in the intervention compared with the control group.
TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT02344576
JAMA Intern Med. 2018;178(4):520-529. doi:10.1001/jamainternmed.2017.8713
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S hared decision making is a process that helps patientsand clinicians align therapieswith patients’ values andpreferences.1 This is particularly important for inva-
sive therapies for life-threatening illness,2,3 such as left ven-
tricularassistdevicesasdestination therapy (DTLVADs).These
devices are offered to patients with severe heart failure who
are ineligible for cardiac transplantation. Placement of a DT
LVAD can be life-prolonging, but also comes with consider-
able changes in lifestyle,need for caregiver support, andahigh
likelihood of complications.4,5 Unfortunately, for many ma-
jor decisions involving newer medical technologies—
includingDTLVAD—education, consent, and shareddecision-
making processes are suboptimal.6,7 Current consent
documents are too long and poorly written,8 industry mate-
rials tend to be biased,9,10 and clinicians often lack the skills
to support high-quality decision making.11
Patientdecisionaidsareaformofdecisionsupportthatstan-
dardize the informationreceivedbypatients tosupportashared
decision-making process.12 Decision aids have been shown to
improve knowledge and reduce decisional conflict.13 How-
ever, few tools have been developed to engage seriously ill pa-
tients inshareddecisionmaking,14anduntil recently,nonewere
available for LVAD.9 In addition, the effectiveness of decision
aids inclinicalpractice is largelyunknownandwide-scale imple-
mentation remains a substantial challenge.15,16
In this context, we performed a series of studies explor-
ing the decisional needs for patients and their caregivers con-
sidering DT LVAD.10,17,18 Based on this research and following
the International Patient Decision Aid Standards (IPDAS), we
developed pamphlet and video decision aids for patients and
their caregivers consideringDTLVAD.19Weaimed to study the
effectiveness of these decision aids coupled with a clinician-
directed support training through a multicenter, cluster-
randomized, stepped-wedge design.
Methods
Design and Sites
TheMulticenter Trial of a Shared Decision Support Interven-
tion for Patients and their Caregivers Offered Destination
Therapy for End-Stage Heart Failure (DECIDE-LVAD) used a
hospital-level, randomizedphased roll out (steppedwedge) in
6 mechanical circulatory support (MCS) programs across the
United States.20,21 This approach was chosen because the in-
tervention engages clinicians and other program staff in ad-
dition to patients.22 The study was overseen by the institu-
tional reviewboardat theUniversityofColoradoandapproved
by institutional review boards at all sites. The trial protocol is
available in Supplement 1.
Study Participants
Patient andcaregiverdyadswereenrolled fromthe6sitesdur-
ing a 20-month enrollment period. Patient eligibility criteria
included age 18 years or older, end-stage heart failure, and
activeconsideration for aDTLVAD.Eligiblepatientswere iden-
tified by the study team at each site at the time a DT LVAD
evaluationwas initiated. Thiswas triggered either by apreau-
thorization request to the patient’s health insurance for LVAD
evaluation or a provider’s request for formal education about
LVAD.Written informed consent was obtained from all study
participants. Participantswere compensated $25 for complet-
ing surveys at each time point.
Intervention
The content anddevelopment of thedecision aids is described
separately19; the pamphlet is available in Supplement 2.
All sitesbegan in thecontrolperiodusing their existingma-
terials during formal education. This process typically con-
sisted of a patient teaching session with an MCS coordinator
and use of industry pamphlets/videos and program-specific
documents. At 4 stepped time intervals, programs were ran-
domly assigned to cross over to the intervention. The deci-
sion support intervention included (1) delivery of a 2.5-hour
clinician-directed decision support training and (2) use of the
26-minute video and 8-page pamphlet decision aids devel-
oped by our group.19 At the time of intervention implemen-
tation, staff directly involved in LVAD patient education and
carewere asked to attenda60-minute grand rounds stylepre-
sentation about shared decision making for DT LVAD, fol-
lowed by a 90-minute coaching session that included dem-
onstrationanddiscussionof thedecisionaidmaterials.20With
facilitation by local physician champions, sites were then in-
structed to formally integrate the decision aids and tenets
learned fromthe coaching session into existing education, de-
cisionmaking, and informed consent processes. The only re-
quirements of sites around the use of the decision aids were
that theybedeliveredbyclinicians andnot research staff. This
designallowedfor sites to implement thedecisionaids inaway
that was most appropriate for that site; thus, local differ-
ences in how the intervention was delivered were possible.
Data Collection
Data collection was the same during both control and inter-
vention periods. For all patients meeting initial eligibility
criteria, basic demographic and health status data were cap-
tured in the screening form. Enrolled participants were ad-
ministered surveys (Supplement 2) at 4 time points: prior to
formal LVAD education (baseline 1), immediately after formal
education (baseline 2), 1 month after enrollment, and
Key Points
Question Does a shared decision support intervention for
patients considering destination therapy left ventricular assist
device (DT LVAD) improve decision quality compared with usual
care?
Findings In this multicenter randomized stepped-wedgeclinical
trial of 248 patients being considered for DT LVAD, compared with
patients in the usual care control period, patients enrolled in the
intervention period had significantly better knowledge and higher
concordance between stated values and patient-reported
treatment choice.
Meaning An intervention supporting shared decisionmaking for
DT LVADwas associated with improved patient decision quality.
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6 months after enrollment. Baseline surveys were adminis-
tered in person (with verbal assessments completed),23-25
whereas follow-up surveys were administered in person or
through telephone or mail. Medical records were reviewed at
enrollment, 1 month, and 6months for relevant clinical infor-
mation, outcomes, and adverse events. Decision aid use by
individual patients was reported by clinical staff. All data
were entered into a REDCap database by the individual
sites.26
Outcomes
Theprimaryoutcomewasdecisionquality: theextent towhich
medical decisionmaking reflects the considered preferences
of a well-informed patient.13,27,28 As such, coprimary end-
points were chosen comprising the 2main IPDAS domains of
decision quality—knowledge and values-choice concor-
dance.
A10-itemknowledge testwasdevelopedbythestudyteam
and validated by clinicians and patients. Consistent with the
methods of Sepucha et al,29 the study team created a list of
knowledge itemsbasedonclinicalneeds, localpost-LVADedu-
cation standards, and needs assessment work with patients.
We then surveyedpatients, caregivers,MCScoordinators, and
physicians to narrow the list and determine the key knowl-
edge itemsandassurecontentvalidity.Theacceptabilityof this
measurewas further assessedwith patients and caregivers in
apilot of the trial protocol.20 Improvement inknowledge from
baseline 1 to baseline 2 was a coprimary endpoint.30 A values
scale was also developed, modeled after a well-accepted val-
ues evaluation tool.31 During previous needs assessment
work,10,17,18 1 value rose above all others in considering DT
LVAD:maximizing chances of survival with aggressivemedi-
cal care vs not.Wedeveloped a single-item, 10-tier Likert val-
ues measure using the dichotomy of “Do everything I can to
live longer, even if thatmeanshavingmajor surgery andbeing
dependentonamachine” (score 1) vs“Livewithwhatever time
I have left, without going throughmajor surgery or being de-
pendent on a machine” (score 10). Concordance between
1-monthvaluescoreandpatient-reported treatmentchoice (DT
LVADormedical treatmentwithout LVAD) at 1monthwas the
other coprimary endpoint. Concordance between 1-month
valuescoreandactual treatment receivedby6monthswasalso
assessed.
Secondary outcomes included validatedmeasures of de-
cision conflict,32 decision regret,33 control preferences,34 ill-
ness acceptance,35 perceived stress,36 depression (Patient
Health Questionnaire-2),37 and quality of life (EuroQol Visual
Analogue Scale).38 Acceptability of the decision aidswas also
measured at baseline 2.39
Analysis
Wedetermined thata sample sizeof 168participantswithstan-
dard deviation of 18% would yield a power of 0.95 to detect
an improvement inknowledgeby 10%.Weanticipatedadrop-
out rateof 25%by6monthsbasedonexpecteddeath rates and
other loss to follow-up.
We compared baseline characteristics between partici-
pants enrolled in the study to those screened but not
enrolled using χ2 tests. We compared characteristics
between those enrolled during the control period with those
enrolled during the intervention period using χ2 tests and t
tests.
To assess the change in patient DT LVAD knowledge over
time, we fit a linearmixedmodel proposed for the analysis of
stepped wedge designs.40 This model accounted for the re-
peatedwithin-personmeasures, included a randomeffect for
site and fixed effect indicators of intervention group and
steppedwedge timeperiod.Thismodel adjusts for trendsover
time,assumingthatchangesoccursimilarlyacrossall sites.Ow-
ing to differences observed at baseline, we included 2 covar-
iate indicatorvariables:outpatient statusanddiagnosisofheart
failure less than 4 years prior to enrollment. We evaluated
whether the change in knowledge score (percent correct) be-
tweenbaseline 1 andbaseline2wasdifferentbetween thecon-
trol and intervention groups.
To assess values-choice concordance, we calculated the
Kendall’s τ correlation coefficient between the stated values
score at 1month andeachof the treatment outcomes (patient-
reported treatment choice at 1 month, actual treatment re-
ceived at 6 months), and looked at the difference in this cor-
relation coefficient by intervention group. To generate a
confidence interval for this difference, we performed 500
bootstrap samples and calculated the 2.5th and 97.5th
percentiles.
In analysis of secondary survey scores described previ-
ously and theLVAD implantation rates by intervention group,
we applied the samemixedmodelmethods described above.
Owing to site differences in LVAD implantation rate and
differences in locationofpatient enrollmentover time,weper-
formed separate sensitivity analyses accounting for each, as
well as sensitivity analysiswithout including the site random
effect. Missing data analyses can be viewed in Supplement 2.
All analyses were performed using SAS statistical soft-
ware (version 9.4, SAS Inc).
Results
Patients
BetweenJune2015andJanuary2017,of 385patientswhowere
actively considering a DT LVAD, 248were enrolled (Figure 1).
Compared with patients whowere screened but not enrolled
in thestudy,enrolledpatientsweremore likely tobewhitenon-
Hispanic (75.8% vs 63.9%, P = .03); other demographics and
clinical status were not different between the 2 groups.
Patients in the intervention periodweremore likely to be
enrolled as outpatient (31%vs 17%,P = .007) and tohavebeen
diagnosedwith heart failure less than 4 years prior (29.8% vs
18.2%, P = .03) than those enrolled in the control period. See
Table 1 for other demographic information.
Exposure to and Impression of Decision SupportMaterials
In the control period, patients most often received site-
specific consent forms, locally made documents, and indus-
try pamphlets/videos during formal education. In the inter-
vention period, 94.7% of patients received the decision aid
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(99 patients received both pamphlet and video, 2 received
pamphlet only, 6 received video only, and 6 received nei-
ther); 3 of the 6 sites stopped using industry pamphlets/
videos labeled as decision making materials. Patient-
reported acceptability of the educational materials was not
significantly different between the control and intervention
periods.
Decision Quality: Knowledge and Values-Choice
Concordance
Patient knowledge (mean test performance) during the deci-
sion-makingperiod improved from59.5%to64.9% in thecon-
trol group vs 59.1% to 70.0% in the intervention group (dif-
ference of difference, 5.5%; P = .03) (Figure 2).
Patient values on the 10-tier Likert scalewere generally in
thedirectionofmore aggressive care tomaximize survival (ie,
closer to 1): control period baseline 1 scoremean of 2.19 (stan-
dard error [SE], 0.26); 1-month, 2.37 (SE, 0.28); 6-month, 3.12
(SE, 0.33); intervention period baseline, 2.98 (SE, 0.30);
1-month, 3.33 (SE, 0.32); 6-month, 3.65 (SE, 0.39); adjusted
overall difference P = .06 (Table 2).
At 1 month, patient-reported treatment choice favored
LVADmore in the control group than the intervention group:
“wanted LVAD and decided to get it” 78.8% control, 54.4%
intervention; “first decided not to get the DT LVAD but then
decided he/she wanted it” 12.5% control, 5.1% intervention;
“decided not to get LVAD” 1.0% control, 7.6% intervention
(overall P < .001).
Concordance between stated values and patient-
reported treatment choice (eg, values score closer to 1 com-
bined with “wanted LVAD”) at 1-month was higher in the
intervention than in the control group (Kendall’s τ correla-
tion coefficient: control 0.17, intervention 0.48 (difference
in correlation control to intervention, 0.28; 95% CI, 0.05-
0.45; P = .01) (Figure 2). Patient-reported treatment choices
were stable from 1 month to 6 months (Table 2).
By 6 months, 110 (83.3%) (adjusted rate, 79.9%) patients
in the control group and 54 (52.4%) (adjusted rate, 53.9%) pa-
Figure 1. Screening and Enrollment FlowDiagram
6 Mechanical circulatory support programs
participating (385 patients)
13 Died
31 Incomplete
3 Withdrew
15 Incomplete
2 Lost to follow-up
6 Incomplete at 1-mo and
died at 6-mo
7 Did not complete 1-mo
follow-up but did complete
6-mo follow-up
8 Died
34 Incomplete
14 Withdrew
12 Incomplete
5 Lost to follow-up
3 Incomplete at 1-mo and
died at 6-mo
4 Did not complete 1-mo
follow-up but did complete
6-mo follow-up
228 Randomized to control group 157 Randomized to intervention group
135 Enrolled in full study 113 Enrolled in full study
104 Completed 1-mo follow-up 79 Completed 1-mo follow-up
98 Completed 6-mo follow-up 67 Completed 6-mo follow-up
1 Withdrew
14 Died
4 Lost to follow-up
5 Lost to follow-up
14 Died
93 Not enrolled in full study
29 Refused participation
27 Not approached by study
coordinator
22 Other
7 Enrolled in medical record
review only
4 Unable to consent
3 LVAD implant prior to consent
1 Died prior to consent
44 Not enrolled in full study
10 Refused participation
8 Enrolled in medical record
review only
6 Other
5 Unable to consent
5 Doctor refused approach
4 Died prior to consent
3 Not approached by study
coordinator
3 LVAD implant prior to consent
385 Patients randomized in 
stepped-wedge randomization
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tients in the intervention group had undergone LVAD
implantation (P = .008), with significant differences among
sites (Figure 3). The medical team decided the patient was
not eligible for a DT LVAD in 11 (8.3%) control and 25 (24.3%)
intervention patients (P < .001). Concordance between
stated values at 1 month and actual treatment received by 6
months (in contrast to the 1-month patient-reported treat-
ment choice above) was the same in both the control and
intervention groups (Kendall’s τ correlation coefficient:
intervention, 0.26; control, 0.27; difference in correlation
control to intervention: 0.01; 95% CI, −0.24 to 0.25;
P = .97).
Secondary Outcomes
At baseline and follow up, decision conflict, decision regret,
controlpreferences, illnessacceptance, stress,depression, and
qualityof lifewerenot significantlydifferentbetween thecon-
trol and intervention groups (Table 2).
Sensitivity Analyses
When individual sites were removed from the analysis or
when the analysis was restricted only to those enrolled in
the inpatient setting, the primary knowledge and values-
choice concordance findings remained significantly in favor
of the intervention period. In sensitivity analysis of the
knowledge score that did not include the site random effect,
our findings remained the same. Missing data can be viewed
in Supplement 2.
Discussion
The DECIDE-LVAD trial offers unique insights into one of the
most challengingmedical decisions createdbymodernmedi-
cine.Rather than test theefficacyofdecision support tools ad-
ministeredbyresearchpersonnel inapatient-randomizedtrial,
this studyusedapragmatic effectivenessdesign to assesshow
programmatic integration of decision aids and clinician
training into standardprocessesof caremay influenceDTLVAD
Table 1. Participant Baseline Characteristics
Characteristic
No. (%)
Control
(n = 135)a
Intervention
(n = 113)a
Age, mean (SD), yb 63.5 (9.7) 63.2 (10.2)
Sex, male 111 (82.2) 98 (86.7)
Race/ethnicityc
White, non-Hispanic 102 (79.1) 86 (82.7)
Black 19 (14.7) 12 (11.5)
Other 8 (6.2) 6 (5.8)
Some college or more 74 (56.4) 72 (69.2)
Receiving disability 35 (27.6) 33 (32.0)
Annual household income <$40 000 64 (51.6) 37 (40.2)
Married 95 (72.5) 68 (65.4)
First diagnosed with heart failure
Within past 2 years 15 (11.9) 12 (12.4)
2-4 years 9 (7.1) 19 (19.6)
4 or more years 102 (81.0) 66 (68.0)
INTERMACS score
1 5 (4.3) 8 (7.9)
2-3 89 (77.4) 48 (47.5)
4-7 21 (18.3) 45 (44.6)
Comorbiditiesd
Peripheral vascular disease 7 (5.2) 4 (3.5)
Major stroke 2 (1.5) 0 (0)
Severe diabetes 12 (8.9) 11 (9.7)
Chronic renal disease 31 (23.0) 23 (20.4)
Pulmonary disease 12 (8.9) 4 (3.5)
Liver dysfunction 6 (4.4) 5 (4.4)
History of solid organ or blood cancer 10 (7.4) 8 (7.1)
History of alcohol or illicit drug use 13 (9.6) 12 (10.6)
Enrollment location
Outpatient 23 (17.0) 35 (31.0)
Inpatient (non-ICU) 83 (61.5) 48 (42.5)
ICU 29 (21.5) 30 (26.5)
Cognitive Function (SPMSQ) Score,
mean (SD)e
0.7 (1.5) 0.7 (1.2)
Intact functioning 123 (93.9) 94 (93.1)
Mild impairment 5 (3.8) 6 (5.9)
Severe impairment 3 (2.3) 1 (1.0)
Literacy (REALM-R) Score, mean (SD)f 6.93 (1.9) 6.95 (2.0)
At risk for poor literacy 30 (23.4) 27 (26.7)
Subjective Numeracy Score, mean (SD)g 4.0 (1.1) 4.2 (1.1)
Abbreviations: ICU, intensive care unit; INTERMACS, Interagency Registry for
Mechanically Assisted Circulatory Support; REALM-R, rapid estimate of adult
literacy inmedicine, revised; SPMSQ, short portablemental status questionnaire.
a Some participants refused to answer certain demographic questions; the
following items hadmissing data: race/ethnicity (n = 15), education (n = 13),
disability status (n = 18), income (n = 32), marital status (n = 13), heart failure
diagnosis timing (n = 25), SPMSQ (n = 16), REALM-R (n = 19), Numeracy Score
(n = 14).
b Reported from patient medical record.
c Patient-reported from survey.
dUsed from INTERMACS preimplant data collection form, section “Concerns
and Contraindications.”
e Number of incorrect answers out of 10 questions.
f Number of correctly read words out of 8 listed.
g Range of 1 to 6, higher numeracy toward 6.
Figure 2. Primary Outcome, Decision Quality
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decision making.22 Through its conduct, DECIDE-LVAD cre-
atedoneof the largest prospectiveLVAD-eligible cohorts,4 en-
rollingmost of thepatients considered forDTLVADduring the
study period, from 6 geographically diverse sites, and nearly
a quarter from intensive care. In this context, the interven-
tion was associated with better decision quality.
Table 2. Outcomes
Outcome Visit Control (n = 132) Intervention (n = 104) P Value
Knowledge score, percent correct (10-item test), mean (SE), %a BL1 59.5 (1.9) 59.1 (2.2) .92
BL2 64.9 (1.8) 70.0 (2.1) .09
1 mo 67.8 (1.9) 66.4 (2.3) .64
6 mo 68.6 (1.8) 67.1 (2.2) .63
Values score (scale 1-10), mean (SE)b BL1 2.19 (0.26) 2.98 (0.30) .06
1 mo 2.37 (0.28) 3.33 (0.32) .03
6 mo 3.12 (0.33) 3.65 (0.39) .32
Treatment choice, “wanted LVAD,” No. (%)c 1 mod 95 (92.2) 47 (61.0) <.001
6 moe 88 (90.7) 46 (69.7) .01
Treatment received, LVAD, No. (%)f 6 mo 110 (83.3) 54 (52.4) <.001
HeartMate IIf 6 mo 68 (61.8) 22 (40.7) .02
HeartMate 3f 6 mo 29 (26.4) 22 (40.7) .02
HVADf 6 mo 10 (9.1) 10 (18.5) .02
Decision conflict part b score (0-100), mean (SE)g BL1 20.2 (1.99) 23.4 (2.24) .28
BL2 16.5 (1.95) 18.4 (2.23) .52
1 mo 15.5 (1.89) 17.9 (2.17) .42
6 mo 15.4 (1.89) 14.2 (2.21) .67
Decision regret score (0-100), mean (SE)h 1 mo 14.3 (2.15) 17.9 (2.84) .37
6 mo 12.1 (2.28) 19.1 (2.96) .09
Control preferences scale (preferred), active role, No. (%)i 1 mod 90 (86.6) 71 (89.8) .87
6 moe 85 (86.7) 61 (92.4) .70
Control preferences scale (actual), active role, No. (%)j 1 mod 91 (87.5) 66 (83.6) .81
6 moe 84 (85.8) 59 (89.4) .95
PEACE: acceptance of illness score (5-20), mean (SE)k BL1 17.5 (0.26) 17.1 (0.31) .44
1 mo 17.4 (0.27) 17.4 (0.32) .90
6 mo 17.5 (0.28) 18.2 (0.34) .18
PEACE: struggle with illness score (7-28), mean (SE)l BL1 14.0 (0.42) 13.1 (0.50) .25
1 mo 13.6 (0.47) 12.9 (0.57) .41
6 mo 12.9 (0.50) 12.0 (0.62) .29
Perceived stress score (0-40), mean (SE)m BL1 16.1 (0.68) 14.1 (0.81) .09
6 mo 12.6 (0.82) 11.9 (1.03) .61
Patient Health Q-2 Score (0-6), mean (SE)n BL1 1.80 (0.21) 1.56 (0.24) .47
1 mo 1.64 (0.23) 1.39 (0.26) .47
6 mo 1.06 (0.21) 0.97 (0.25) .80
EuroQol visual analogue scale (0-100), mean (SE)o BL1 44.6 (2.69) 48.6 (3.07) .36
1 mo 64.3 (2.67) 60.5 (3.13) .38
6 mo 69.6 (2.57) 68.8 (3.07) .86
Abbreviations: BL1, baseline 1 survey; BL2, baseline 2 survey; PEACE, peace,
equanimity, and acceptance in the cancer experience; SE, standard error;
1 mo, 1-month follow-up; 6mo, 6-month follow-up.
a 10-Itemmeasure assessing knowledge of DT LVAD, number of correct
answers.
b Likert scale of 1 to 10, with 1 being “Do everything I can to live longer, even if
that means havingmajor surgery and being dependent on amachine” and 10
being “Live with whatever time I have left, without going throughmajor
surgery or being dependent on amachine.”
c Patient-reported treatment decision of “I wanted the DT LVAD and decided to
get it” and “I first decided not to get the DT LVADbut then decided I wanted it.”
dMissing 1-month surveys: 31 (23%) in control group and 34 (30.1%) in
intervention group.
e Missing 6-month surveys: 37 (27.4%) in control group and 46 (40.7%) in
intervention group.
f Medical record report at 6months on patients’ treatment received, LVAD or
no LVAD.
g 16 Items, scoring 0 to 100with higher score indicating greater decisional
conflict.
h 5 Items, scoring 0 to 100with higher score indicating greater decision regret.
i 1 Item assessing preferred control in decisionmaking, “active role” includes
answers of “I prefer to make the final selection about which treatment I will
receive,” “I prefer to make the final selection of my treatment after seriously
considering my doctor’s opinion,” or “I prefer that my doctor and I share
responsibility for deciding which treatment is best.”
j 1 Item assessing actual control in decisionmaking, “active role” includes
answers of “I made the final selection about which treatment I would receive,”
“I made the final selection of my treatment after seriously considering my
doctor’s opinion,” or “My doctor and I shared responsibility for deciding which
was treatment best for me.”
k Questions 1 through 5 of 12 items, scoring 5 to 20with higher score indicating
greater acceptance of illness.
l Questions 6 through 12 of 12 items, scoring 7 to 28 with higher score indicating
greater struggle with illness.
m 10 Items, scoring 0 to 40with higher score indicating greater stress.
n 2 Items, score of 0 to 6 with higher score indicating greater depression.
o 1-Item scale, score of 0 to 100with 0 being “worst imaginable health state”
and 100 being “best imaginable health state.”
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Decision support studiesmost commonlymeasureknowl-
edge and decision conflict as the primary outcomes.13 How-
ever, central to a high-quality decision is whether the choice
matches the patient’s values, goals, and preferences. Knowl-
edge alone is insufficient to guarantee high-quality decision
making,particularly for emotionally chargeddecisionsaround
life and death.41 Similarly, nudging patients in fear and denial
to address life-threatening situations—rather than providing
them with false reassurances—may transiently increase feel-
ings of conflict, anxiety, and even regret.42 Thus, it is not sur-
prisingtousthatDECIDE-LVADinterventiondidnotreducecon-
flict at 1 month; we predicted this a priori.43 In contrast, we
leveraged the dominant value that emergeswhen considering
DTLVAD(ie,aggressivecaretooptimizesurvivalchancesvsnot)
and found that the interventionwas associatedwith improved
concordancebetweenstatedvaluesandpatient-reported treat-
ment choice. This did not translate to improved concordance
between stated values and actual treatment received, perhaps
because DT LVAD implantation is influenced by a wide range
of factors (eg,medical eligibility, presenceof anadequate care-
giver), many of which are not in the patient’s control.
The site-based intervention with a randomized stepped
wedgerolloutdistinguishes theDECIDE-LVADstudyfrommost
other assessments of shared decisionmaking. Despite strong
efficacy data, uptake of decision aids in routine practice has
been slow.16 To be successful, decision support toolsmust in-
tegrate easily into existing care and facilitate necessary dis-
cussions. Leveraging the formal consent and education pro-
cess for LVAD, we were able to implement the DECIDE-LVAD
intervention into this existing structure, while observing the
programmatic transitions in all 6 sites over time. Given the
importance of widespread adoption of shared decision mak-
ing, pragmatic studies such as this one are needed to address
real-world complexities and implementation challenges. The
decrease in device implantation rates from control to inter-
vention in 5 of the 6 sites supports the ability to influence in-
stitutional culture and decision-making processes related to
major medical interventions.44
Unlike most prospective studies in MCS that follow pa-
tients fromthetimeof implant, theDECIDE-LVADstudymoved
upstream to follow the entire population of patients formally
consideredforDTLVAD.45,46Byfocusingonachoicerather than
Figure 3. LVAD Implant by 6Months
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Abbreviation: LVAD, left ventricular assist device.
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a specific therapy (ie, only thosewho have received an LVAD),
DECIDE-LVAD expands insights into the patients, experi-
ences, and processes that lead up to decisions about device
implantation.47 We found that a significant number of pa-
tients facinghighmorbidityandmortality fromheart failurede-
clineDTLVADinfavorofavoidingaggressivetherapies.Thedec-
linationratesreportedhereareamongpatientswhohaveagreed
to undergo formal evaluation; thus, we suspect that DT LVAD
declinationmaybemoreprevalent inthebroadercommunity.48
This is concordantwithpriorworkshowingdiversity in therela-
tiveemphasispatientsplaceonqualityvsquantityof life, even
when actively facing life-threatening illness.17,49 It also rein-
forces DT LVAD as a relatively preference-sensitive decision.
Limitations
A number of limitations should be recognized. First, missing
data were somewhat frequent and concentrated among the
group of patients who did not undergo implantation of DT
LVAD.Deathwas themost commoncauseofmissingdata, fol-
lowed by withdrawal from the study, both of which are com-
mon in studies targeting patients with life threatening ill-
ness. Our missing data rates are comparable to similar study
types,43,45 and ourmodels adjusted formissing data asmuch
as possible. Second, time trends in rapidly evolving fields are
particularlyproblematic for thesteppedwedgedesign.21,40For-
tunately,device technologywas relatively stablebetween2015
and 2017 and durable LVAD implant rates across the US pla-
teaued somewhat during this period.48 Third, the phased
implementation randomized the sitewith the lowestLVAD im-
plant rate to spend themost time in the intervention and the
site with the highest LVAD implant rate to spend the most
time in the control. Linear mixed models accounting for site
effects and sensitivity analyses were used to explore and di-
minish these differences for the patient-based effectiveness
outcomes, but do not necessarily fully account for such
effects.40 Finally, the populationwasmostlywhitemales. Al-
though enrolleeswere 12%more likely to bewhite than those
excluded, the final study cohort reflects contemporary use of
LVADs in the United States.50,51 This bias makes it difficult to
extrapolate the findings here to decision making for women
and underrepresented races/ethnicities.
Conclusions
A shared decision-making intervention for patients consider-
ing DT LVAD—implemented programmatically, integrating
novel patient decision aids, and including clinician training—
was associatedwith a significant improvement in knowledge
andan increase in concordancebetween statedvalues andpa-
tient-reported treatment choice. Although these changes did
not translate to improvements in concordancebetween stated
values andactual treatment received, patientswere less likely
during intervention than control to proceed to LVAD implant.
These results suggest that institutional culture and processes
can influence medical decisions in life-threatening illness.
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